- Home
- ZVSA vs GLMD Comparison
ZVSA vs GLMD Comparison
Compare ZVSA & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZVSA
- GLMD
- Stock Information
- Founded
- ZVSA 2014
- GLMD 2000
- Country
- ZVSA United States
- GLMD Israel
- Employees
- ZVSA N/A
- GLMD N/A
- Industry
- ZVSA Biotechnology: Pharmaceutical Preparations
- GLMD Biotechnology: Pharmaceutical Preparations
- Sector
- ZVSA Health Care
- GLMD Health Care
- Exchange
- ZVSA Nasdaq
- GLMD Nasdaq
- Market Cap
- ZVSA 3.0M
- GLMD 3.0M
- IPO Year
- ZVSA N/A
- GLMD 2014
- Fundamental
- Price
- ZVSA $0.69
- GLMD $1.81
- Analyst Decision
- ZVSA
- GLMD Hold
- Analyst Count
- ZVSA 0
- GLMD 1
- Target Price
- ZVSA N/A
- GLMD N/A
- AVG Volume (30 Days)
- ZVSA 1.5M
- GLMD 364.3K
- Earning Date
- ZVSA 08-08-2025
- GLMD 05-22-2025
- Dividend Yield
- ZVSA N/A
- GLMD N/A
- EPS Growth
- ZVSA N/A
- GLMD N/A
- EPS
- ZVSA N/A
- GLMD N/A
- Revenue
- ZVSA N/A
- GLMD N/A
- Revenue This Year
- ZVSA N/A
- GLMD N/A
- Revenue Next Year
- ZVSA N/A
- GLMD N/A
- P/E Ratio
- ZVSA N/A
- GLMD N/A
- Revenue Growth
- ZVSA N/A
- GLMD N/A
- 52 Week Low
- ZVSA $0.47
- GLMD $1.15
- 52 Week High
- ZVSA $6.30
- GLMD $23.80
- Technical
- Relative Strength Index (RSI)
- ZVSA 53.43
- GLMD 61.13
- Support Level
- ZVSA $0.61
- GLMD $1.63
- Resistance Level
- ZVSA $0.73
- GLMD $1.94
- Average True Range (ATR)
- ZVSA 0.07
- GLMD 0.12
- MACD
- ZVSA 0.00
- GLMD 0.01
- Stochastic Oscillator
- ZVSA 36.53
- GLMD 69.77
About ZVSA ZyVersa Therapeutics Inc.
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.